Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Single-arm, Phase 2 Study of Initial Treatment With Elotuzumab, Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (E-KRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy

Next Previous
Trial Profile

Open-label, Single-arm, Phase 2 Study of Initial Treatment With Elotuzumab, Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (E-KRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Elotuzumab (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms MMRC

    • Most Recent Events

    • 12 Dec 2023 Results assessing concordance and prognostic significance of early MRD status after 4 cycles of treatment with Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) by next generation sequencing (NGS) in both the bone marrow and peripheral blood and by International Myeloma Working Group (IMWG) response criteria, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 26 Apr 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Mar 2025.
    • 12 Nov 2021 Planned End Date changed from 1 Dec 2022 to 1 Mar 2029.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top